Literature DB >> 12939747

Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia.

Sabrina Tosi1, Jim Hughes, Stephen W Scherer, Kazuhiko Nakabayashi, Jochen Harbott, Oskar A Haas, Giovanni Cazzaniga, Andrea Biondi, Helena Kempski, Lyndal Kearney.   

Abstract

The t(7;12)(q36;p13) is a recurrent chromosome abnormality in infant leukemia. In these cases, the involvement of ETV6, with disruption of the gene consistently at its 5' end, has been reported by several groups. A fusion transcript between ETV6 and HLXB9 has been detected in some, but not all, reported cases of t(7;12). We report here a study based on fluorescence in situ hybridization (FISH) mapping of the translocation breakpoints in seven patients and detailed molecular studies using Southern blotting on two of these patients. The FISH studies have shown a cluster of breakpoints within a cosmid contig proximal to the HLXB9 gene. Southern blotting analysis enabled us to define two distinct breakpoints within the area covered by the cosmid contig in two patients. The analysis of an unusual case of t(7;12)(q22;p13) [full karyotype: 46,XX,der(7)t(7;12)(q22;p13)del(7)(q22q36)] also revealed a break in 7q36, although in a region proximal to the overlapping cosmids. 5' RACE PCR in one patient has shown a rearrangement involving the ETV6 allele not involved in the t(7;12), suggesting that no functional ETV6 allele might be present in this case. These data show some heterogeneity in the distribution of breakpoints in 7q36, indicating that the generation of a fusion gene might not be the mechanism responsible for leukemogenesis in the t(7;12), at least in some cases. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939747     DOI: 10.1002/gcc.10258

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Homeobox protein HB9 binds to the prostaglandin E receptor 2 promoter and inhibits intracellular cAMP mobilization in leukemic cells.

Authors:  Sarah Wildenhain; Deborah Ingenhag; Christian Ruckert; Özer Degistirici; Martin Dugas; Roland Meisel; Julia Hauer; Arndt Borkhardt
Journal:  J Biol Chem       Date:  2012-10-08       Impact factor: 5.157

2.  Engineered model of t(7;12)(q36;p13) AML recapitulates patient-specific features and gene expression profiles.

Authors:  Denise Ragusa; Ylenia Cicirò; Concetta Federico; Salvatore Saccone; Francesca Bruno; Reza Saeedi; Cristina Sisu; Cristina Pina; Arturo Sala; Sabrina Tosi
Journal:  Oncogenesis       Date:  2022-09-03       Impact factor: 6.524

3.  An induced pluripotent stem cell t(7;12)(q36;p13) acute myeloid leukemia model shows high expression of MNX1 and a block in differentiation of the erythroid and megakaryocytic lineages.

Authors:  Tina Nilsson; Ahmed Waraky; Anders Östlund; Susann Li; Anna Staffas; Julia Asp; Linda Fogelstrand; Jonas Abrahamsson; Lars Palmqvist
Journal:  Int J Cancer       Date:  2022-06-03       Impact factor: 7.316

Review 4.  Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literature.

Authors:  Farhat Abbas Bhatti; Iftikhar Hussain; Muhammad Zafar Ali
Journal:  J Hematol Oncol       Date:  2009-06-21       Impact factor: 17.388

5.  A Novel Three-Colour Fluorescence in Situ Hybridization Approach for the Detection of t(7;12)(q36;p13) in Acute Myeloid Leukaemia Reveals New Cryptic Three Way Translocation t(7;12;16).

Authors:  Abdulbasit Naiel; Michael Vetter; Olga Plekhanova; Elena Fleischman; Olga Sokova; Grigory Tsaur; Jochen Harbott; Sabrina Tosi
Journal:  Cancers (Basel)       Date:  2013-03-11       Impact factor: 6.639

Review 6.  Paediatric acute myeloid leukaemia with the t(7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspects.

Authors:  Sabrina Tosi; Yasser Mostafa Kamel; Temitayo Owoka; Concetta Federico; Tony H Truong; Salvatore Saccone
Journal:  Biomark Res       Date:  2015-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.